Bioverativ

Bioverativ. It was a biotechnology company focused on the research, development, and commercialization of therapies for hemophilia and other rare blood disorders. Spun off from Biogen in 2017, the company was headquartered in Waltham, Massachusetts and became a publicly traded entity on the NASDAQ under the ticker symbol "BIVV". The firm's operations were centered on advancing innovative treatments for patients with hemophilia A and hemophilia B, leveraging expertise in blood clotting factors and novel therapeutic approaches.

History

The company's origins trace directly to its separation from its parent firm, Biogen, a process completed in February 2017. This corporate spin-off was designed to allow both entities to concentrate on their respective core therapeutic areas, with the new company taking ownership of Biogen's established hemophilia business. Key leadership, including Chief Executive Officer John G. Cox and Chief Scientific Officer Gaston Picchio, were instrumental in guiding the nascent firm. The initial public offering was a significant event in the biotechnology industry, creating an independent company dedicated to hematology. Prior to the spin-off, the hemophilia assets were part of Biogen's portfolio following its earlier acquisition of Syntonix and subsequent development work.

Products and pipeline

The company's commercial portfolio was built upon two flagship products for hemophilia: Eloctate (Antihemophilic Factor (Recombinant), Fc Fusion Protein) for hemophilia A, and Alprolix (Coagulation Factor IX (Recombinant), Fc Fusion Protein) for hemophilia B. Both therapies utilized Fc fusion technology, licensed from ImmunoGen, to extend the circulating half-life of the clotting factor, reducing the frequency of prophylactic injections for patients. Beyond these marketed products, the research pipeline included investigational compounds like BIVV001 (formerly rFVIIIFc-VWF-XTEN), a novel factor VIII therapy designed for once-weekly dosing. The pipeline also explored treatments for sickle cell disease and beta thalassemia through research collaborations, including work with Sangamo Therapeutics utilizing zinc finger nuclease technology.

Corporate affairs

As an independent entity, the company maintained its global headquarters in Waltham, Massachusetts, employing approximately 450 people dedicated to research, commercial operations, and support functions. Financially, it reported substantial revenue driven by Eloctate and Alprolix, with a significant portion generated in the United States and other key international markets like Europe and Japan. The corporate strategy emphasized both the growth of its commercial products and strategic business development, including the aforementioned collaboration with Sangamo Therapeutics. The company operated under the regulatory oversight of bodies such as the U.S. Food and Drug Administration and the European Medicines Agency.

Clinical development

Clinical development activities were central to the company's mission, with multiple programs advancing through clinical trials. The most advanced program beyond its marketed products was BIVV001, which progressed through Phase 1/2a studies to evaluate its safety, tolerability, and pharmacokinetics in patients with hemophilia A. Another significant program involved the collaboration with Sangamo Therapeutics on ST-400, an ex vivo gene editing therapy for beta thalassemia, and BIVV003 for sickle cell disease; these investigational therapies entered early-stage clinical testing. These trials were conducted at major medical centers and research institutions worldwide, contributing data to regulatory submissions.

Acquisition by Sanofi

In January 2018, the French pharmaceutical giant Sanofi announced a definitive agreement to acquire the company for approximately $11.6 billion. The transaction, structured as a cash tender offer, was completed in March 2018, with Sanofi paying $105 per share. This acquisition was a major consolidation move within the pharmaceutical industry, allowing Sanofi to significantly bolster its presence in the specialized area of rare diseases and hematology. Following the acquisition, the company's operations, products, and pipeline were fully integrated into Sanofi's specialty care global business unit, ceasing to exist as an independent entity on the NASDAQ.

Category:Biotechnology companies of the United States Category:Companies based in Massachusetts Category:Companies listed on NASDAQ Category:Pharmaceutical companies established in 2016 Category:Pharmaceutical companies disestablished in 2018